Beyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environment Authors: Consuela Coni Dennis, Victoria Bouhairie Published: 2026 ABSTRACT AbstractContinuous glucose monitoring (CGM) improves glycemic control and reduces acute events, yet adoption remains low despite expanded coverage. Real-world evidence shows that most eligible patients do not use CGMs, highlighting a gap between access and utilization. This commentary examines key barriers, including provider knowledge gaps, administrative complexity, workflow constraints, and persistent socioeconomic inequities. We argue that coverage expansion alone is insufficient to drive uptake. Coordinated strategies that support prescriber education, streamline processes, and integrate CGM into routine care are needed. Addressing these systemic and behavioral barriers is essential to realizing the full clinical and economic benefits of CGM at scale.Keywords: Continuous glucose monitoring, CGM utilization, Diabetes management, Primary care, Glycemic control, Health disparities, Patient adherence, Digital health Key Summary Points Continuous glucose monitoring (CGM) delivers clear clinical and economic benefits yet remains substantially underutilized among eligible patients.Expanded coverage has not translated into meaningful 34 uptake, highlighting the limitations of access-focused policy approaches.The primary barriers to CGM adoption are systemic—not technological—including provider knowledge gaps, administrative burden, and fragmented care workflows.Achieving equitable and scalable CGM adoption will require coordinated action beyond coverage, including provider education, workflow integration, and reduction of structural barriers Introduction About 40 million adults in the U.S., or roughly 1 in 8 individuals, are living with diabetes, incurring approximately $413 billion in direct and indirect costs per year [1, 2]. By 2030, the number of people with diabetes is projected to reach at least 50 million [3], significantly adding to the clinical, social, and financial burdens associated with this chronic condition. The growing scope and scale of diabetes in the U.S., combined with ongoing adoption of value-based care models, have made it even more important to help individuals get ahead and stay ahead of chronic disease management. Digital tools that support real-time, informed, and personalized decision-making, such as CGMs, are a centerpiece of these efforts. CGMs have consistently demonstrated clinical value for diabetes management among individuals who are eligible for their use, including improved glycemic control and reductions in acute events [4, 5]. This evidence has prompted policymakers to expand coverage of CGM devices [6], operating under the assumption that easier, more affordable access would translate into broader adoption and more significant positive outcomes for populations at scale. However, emerging real-world evidence shows that expanded eligibility alone may not be enough to drive adoption. In a large retrospective analysis of more than 3 million individuals from multiple payer types using rapid- or short-acting insulin, CGMs were indeed associated with lower total healthcare costs, fewer emergency department visits and hospitalizations, and improved glycemic outcomes [7]. Yet between 2017 and 2021, approximately 83% of eligible individuals had no evidence of CGM use, despite the technology being available to a large proportion of the cohort [7]. This disconnect raises a critical question: If clinically appropriate patients are not using CGMs even when they are eligible, then what factors are preventing them from doing so? It is also worth noting that the scope of the eligible population is itself expanding. Growing evidence supports the benefit of CGM in individuals with type 2 diabetes who are not treated with insulin, with recent studies and meta-analyses demonstrating improvements in glycemic control, glycemic awareness, and patient self-management in this group [8–11]. As coverage and clinical guidance evolve to reflect this evidence, the population that stands to benefit from, but may not be accessing, CGM use is likely to grow considerably. Evidence from the clinical care environment indicates that structural and behavioral barriers, affecting both prescribers and patients, may play a greater role than benefit design alone. The challenge for policymakers, healthcare leaders, and partner organizations is how to break down these constraints to ensure that eligible patients are getting access to these game-changing devices and that prescribing providers have the support they need to assist patients with utilizing their CGMs appropriately as part of a collaborative diabetes management process. Without addressing the practical realities of how CGMs are introduced, managed, and sustained in the real world of patient care, even high-value interventions might fail to live up to their promises of improved diabetes experiences and outcomes. While the barriers and opportunities discussed in this commentary are grounded primarily in the United States healthcare context—including Medicare and Medicaid coverage structures, commercial payer dynamics, and primary care workflows—many of the underlying challenges around provider education, administrative complexity, and patient engagement are not unique to the U.S. and may resonate across a range of healthcare systems internationally. Note that this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Identifying Systemic and Behavioral Barriers to CGM Uptake Accessibility and affordability are always major issues where healthcare technology is concerned, which is why in 2023, Medicare expanded CGM device coverage to include “all insulin-dependent people and those with a history of problematic hypoglycemia,” creating stronger alignment with existing guidelines from the American Diabetes Association [12]. At least 1.5 million additional Medicare and Medicare Advantage beneficiaries have become eligible for CGM coverage since the change [12]. However, commercial plans and state Medicaid agencies have not uniformly followed suit. Coverage under private insurance plans remains fragmented, and there is no consistent coverage policy across state Medicaid plans [13], even though most states do offer some type of CGM coverage. While the unpredictability of coverage outside of Medicare is certainly an important issue, there are additional challenges at the systemic, practice, and individual levels that may have an even greater influence on whether patients are offered CGMs, how they maintain adherence, and how information from CGM devices is used to inform care decisions (Fig. 1). Barriers to CGM adoption across the care continuum Knowledge and Comfort Gaps Among Primary Care Providers Primary care providers (PCPs) manage around 90% of patients [14] with diabetes, yet many PCPs report knowledge and confidence gaps around how and when to prescribe CGMs and what to do with the data if a patient is using a device [15]. PCPs are generally aware of CGM technology, and many are eager to bring these devices to their patients. In one qualitative study, less than half of PCPs had ever prescribed a CGM, yet nearly three-quarters would be interested in doing so if they had the training and resources [16]. Familiarity with CGM devices has also been identified as a key predictor of prescribing behavior, underscoring the role of practical experience in driving adoption [17]. Effective training will need to help PCPs and their staff address widespread uncertainties such as how to evaluate a patient for clinical eligibility and how to navigate the insurance coverage process, which can include complex and time-consuming administrative tasks [18]. Addressing these obstacles will also require reframing CGMs from a specialty device into a tool that can simplify treatment in the primary care environment. At the moment, the majority of CGM prescriptions often come from the endocrinology environment, with PCPs ordering fewer than 1 in 5 devices [19]. In practice, lack of confidence and familiarity with CGMs can lead to under-prescribing even in populations that are clinically eligible. Socioeconomic Factors and Patient Characteristics Structural inequities, including the social determinants of health, also influence limited prescribing of CGMs, even among individuals identified as eligible for use. Some patient groups have historically experienced inequities in access to healthcare technologies due to perceptions that they are not interested, able, or willing to adopt new tools. These biases are often related to age, technical ability, overall health literacy, financial barriers, or perceived emotional readiness to commit to a new self-management routine. Inequities in CGM uptake can be particularly apparent among older patients, Black and Hispanic patients, publicly insured or uninsured individuals, and those who may exhibit less upfront comfort with technology [20, 21]. These groups are also more likely to experience challenges when navigating the administrative side of the health system, even if they are technically eligible for coverage of a CGM device. Nearly 1 in 4 adults have reported skipping or delaying care due to administrative requirements, with lower-income and minority populations more likely than others to experience negative impacts tied to paperwork issues [22]. Socioeconomic and structural barriers to care are real for many patients, and they can influence how and when CGM devices are introduced in clinical care. Ensuring that all clinically appropriate patients have equitable access to CGM therapy, along with the education, support, and resources needed to use these devices effectively, will be essential to improving adoption and long-term engagement. Yet even when access challenges are overcome, and CGM therapy is initiated, factors affecting sustained use may persist. Alarm fatigue caused by frequent, non-personalized alerts has been identified as a leading driver of CGM discontinuation, contributing to disrupted sleep and reduced engagement [23]. Information overload may also undermine self-efficacy when patients are repeatedly confronted with out-of-range readings without adequate support for interpretation [24]. In addition, physical wearability concerns, including skin irritation and the visibility of a worn sensor, have been documented as reasons for discontinuation. As Barnard-Kelly and colleagues have argued, greater personalization throughout the CGM journey, particularly around usability, psychosocial readiness, and individual lifestyle context, is essential to realizing the full benefit of these devices [25]. Onboarding, Operational, and Data Management Burdens Even when providers do prescribe CGMs, the processes of onboarding patients and integrating the data they generate into treatment present a distinct set of challenges. Time and staffing constraints in the PCP environment create fundamental problems with successfully onboarding patients who may not receive adequate device education. PCPs have reported not having enough time to adequately discuss CGMs with their patients during appointments, with more than half of primary care offices saying they lack the in-house resources for CGM initiation [16, 18]. Lack of bandwidth can also impact a practice’s ability to analyze and act upon CGM data at scale. Primary care providers, especially those who have already expressed uncertainty around interpreting ambulatory glucose profile (AGP) data [26], may not have the clinical staffing or technical resources to review CGM data in a timely and effective manner, which creates additional challenges when trying to use this information to make treatment adjustments. From Awareness to Action: Opportunities to Support Expanded Utilization of CGMs If the healthcare system is not structured to support the consistent and equitable use of CGMs, then expanded coverage is never going to be enough to make an impact on utilization rates. Closing the gap between coverage and uptake requires coordinated action across providers, health plans, and patients to enhance the knowledge and capacity of prescribers while holistically engaging with CGM users throughout their treatment journey. Empowering Prescribers with Knowledge and Resources to Appropriately Initiate CGM Therapy Improving provider confidence and familiarity with CGM therapy must begin with targeted education that embraces the realities of the current primary care environment. Educational strategies that center on practical prescribing workflows and tips for navigating administrative processes may be more successful than traditional approaches. Content should include realistic, varied case studies about diverse patient populations, as well as insights on how to best integrate family members and caregivers into CGM therapy. In addition, educational programming must include clear guidance for prescribers on how to set realistic expectations for follow-up and ongoing management to set patients up for success with adherence within the scope of the patient–provider relationship. From a technical perspective, digital tools intelligently embedded into the workflow can assist with decision-making by providing suggestions for eligibility, flagging potential barriers to adherence, and translating CGM data insights to inform effective treatment decisions. Artificial intelligence is rapidly opening up new possibilities in this area, potentially expanding capacity for primary care providers to identify appropriate candidates, navigate prescribing pathways, and have personalized, data-driven discussions about CGM therapy with their patients [27]. Scalable digital education initiatives offer a complementary avenue for reaching both providers and patients efficiently. Web-based courses, asynchronous training modules, and video tutorials can extend CGM education beyond traditional in-person formats, enabling providers to build familiarity with prescribing workflows and AGP data interpretation at their own pace. For patients, particularly for individuals who may face barriers to regular in-person follow-up, digital education platforms can reinforce device onboarding, support troubleshooting, and promote sustained engagement with CGM therapy. It is also worth acknowledging that current industry investment in CGM education does not always align with what is most needed at the clinical level. Resources have at times been directed toward commercial promotion and device awareness rather than toward the structured, long-term educational programming that would meaningfully improve provider confidence and patient outcomes. Greater investment in practical training initiatives such as hands-on prescribing simulations, case-based learning, and longitudinal support for both clinicians and patients would help ensure that CGM education translates into safer, more effective, and more sustained device use in real-world clinical settings. It is important to acknowledge, however, that decentralizing CGM management to primary care does not mean that all CGM-related complexity can or should be managed there. In real-world practice, maintaining current expertise in CGM platform interpretation can be challenging for clinicians who manage only a small number of CGM users, particularly given the rapid evolution of device software and data visualization tools. A more realistic and sustainable model is a tiered approach in which primary care providers handle initiation and routine monitoring for the majority of patients, while clearly defined referral pathways to specialized diabetes centers or multidisciplinary teams are preserved for more complex cases. Strengthening collaboration between primary care and specialist networks, rather than positioning them as alternatives, will be essential to ensuring that expanded CGM access translates into appropriately managed, high-quality care across the full spectrum of patient complexity. The combination of education and technology around CGMs can help to normalize the use of these devices in the primary care setting and reposition CGM therapy from a specialty intervention to a manageable, mainstream component of diabetes management for eligible individuals. Addressing Structural and Systemic Barriers to Equitably Expand Access to CGMs Policymakers, providers, and payers must all play a role in continuing to reduce systemic challenges to CGM uptake, particularly among historically underserved populations who are disproportionately affected by diabetes and its complications [28]. While Medicare’s coverage changes are an encouraging step, patients often still face roadblocks from variable benefit design from other payers, such as cost sharing, prior authorization requirements, and even physically accessing devices and supplies through payer-preferred distribution channels. Simplifying prior authorization requirements; standardizing documentation expectations; and aligning on distribution pathways to reduce delays, uncertainty, and time spent on administrative tasks can provide significant relief for providers and for patients. Further clarity around coverage criteria and out-of-pocket costs can also help patients initiate CGM therapy with more confidence and reduce downstream friction that may lead to discontinuation. Payers and prescriber organizations will also need to consider how to embed clinical education, coaching, and administrative resources within their diabetes management programs to fully support patients with onboarding, adherence, and troubleshooting. Device manufacturers are also important stakeholders whose decisions meaningfully shape the accessibility and real-world effectiveness of CGM therapy. Pricing policies directly influence affordability for patients and the feasibility of coverage expansion by payers; without manufacturer-level commitment to accessible pricing, coverage gains may not translate into actual device use, particularly for lower-income populations. Manufacturers can also drive adoption through investments in usability improvements such as better alarm customization, more comfortable adhesives, and more discreet device profiles, all of which directly address the patient-level barriers to sustained engagement discussed earlier in this commentary. Technical support for clinicians, including electronic health record (EHR) integration partnerships, clinical decision support tools, and streamlined onboarding resources, can reduce the operational burden that currently limits CGM initiation in primary care. Finally, as noted above, redirecting a greater share of industry investment from commercial promotion toward structured, practical education for both healthcare professionals and patients would help ensure that broader device availability translates into safer and more effective use. A comprehensive strategy to expand CGM utilization must therefore engage manufacturers not only as innovators, but also as active partners in implementation. Expanding proactive, targeted outreach strategies to connect with individuals living with diabetes who are likely to be experiencing socioeconomic barriers to care will also be a critical component of structural transformation. Connecting with these groups as early as possible in the care process can offer more equitable access to health system resources—and help ensure that CGM devices are not limited only to those who are most able to navigate the system independently. Developing Sustainable Infrastructure to Manage CGM Therapy at Scale Supporting ongoing use of CGM for larger numbers of patients in the primary care environment will require a realistic, replicable, and scalable approach to redesigning the diabetes care workflow. In team-based care environments, task sharing can be an effective strategy for ensuring patients get all the information they need to initiate and sustain CGM therapy [29]. Redistributing onboarding responsibilities across the care team can reduce direct burdens on physicians and leverage the unique skills of nurses, medical assistants, pharmacists, and diabetes educators to provide device training and initial troubleshooting. The American Diabetes Association’s Standards of Care [30] emphasize the role of task sharing in effective CGM management, while the American Academy of Family Physicians is among several professional organizations offering blueprints for organizing team-based practice workflows. At the point of care, practices may also consider developing standardized onboarding materials for patients, including written instructions, checklists, or video content, that address common concerns. This can save time for care team members while improving the consistency of education and giving patients something they can take home, review with caregivers, and revisit in the future. To improve the efficiency of CGM data review and subsequent care decisions, practices will need to establish defined workflows that leverage embedded analytics tools. Practices may assign preliminary data triage to trained staff but may also wish to incorporate digital platforms that offer automated summaries of data trends rather than relying on a full, manual interpretation of AGP reports for each patient. Further integrating CGM device data into the EHR, where possible, can reduce workflow fragmentation and support the use of this information in routine decision-making. Finally, prescribers will need to develop structured follow-up processes that encourage patients to raise potential issues before they cascade into treatment nonadherence and potentially avoidable acute events. Exploring strategies such as remote monitoring or asynchronous communication can keep patients connected between scheduled visits, while continuously reinforcing education with proactive outreach through patient-preferred communication channels can sustain user confidence and help maintain consistent adherence. Conclusions Limited CGM adoption is not the failure of any single stakeholder but a reflection of a systemwide challenge shaped by overwhelming clinical demand and longstanding structural inertia. Identifying these barriers is the first step toward implementing solutions that are cost-effective, efficient, and scalable, even as the prevalence of diabetes is projected to rise significantly over the next few years. As consumer expectations for technology-enabled chronic disease management also increase in intensity, the systems that support implementation of device-driven strategies must become strong enough to manage the increased load. Bridging the gaps between the current environment, where CGMs are dramatically underutilized, and a future state in which all clinically eligible patients are equipped with appropriate options for CGM therapy will require coordinated effort from providers, health plans, patients, caregivers, and policymakers. These efforts must address all the key touchpoints of the CGM therapy journey, from prescriber initiation and administrative approval to patient education and ongoing adherence. If the health system evolves to prioritize affordable, equitable access to CGM therapy, it will catalyze positive clinical outcomes for patients, reduce financial burdens on the health system, and provide better experiences for all. Medical Writing/Editorial Assistance The authors wish to thank Jason Allaire, PhD, of Generativity Health Economics and Outcomes Research and KT McGraw of AMP Communications for their assistance with the manuscript. Author Contributions Consuela Dennis contributed to the conceptualization of the manuscript, interpretation of evidence, clinical framing, and drafting of the initial manuscript. Victoria Bouhairie contributed to the conceptualization, clinical framing, and critical revision of the manuscript for important intellectual content. Funding The writing of this manuscript was funded by CCS Medical. The journal’s Rapid Service Fee was funded by CCS Medical. Data Availability No Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Declarations Conflict of Interest Consuela Dennis is an employee of CCS Medical, while Victoria Bouhairie is an employee of Parry’s Wellness and Diabetes Center, PLLC, and do not report any additional conflicts of interest. Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. References Associated Data Data Availability Statement No Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.